COVID-19 mini-review: D614G mutation as an independent risk-factor to the expression of ACE2 and DPP4 associated increased severity in COVID-19
The novel coronavirus 2019 (COVID-19) has struck more than 99 million people worldwide and had claimed more than 2 million lives as of 23 January 2021, which affecting 221 countries/nations. Until now, the pandemic has not shown signals of slowing down, with no proven vaccine in sight. People are sp...
Main Authors: | Siti Asmaa Mat Jusoh (Author), Parisa Foroozandeh (Author), Lee, Yan Fen (Author), Mardani Abdul Halim (Author), Manoj Kumar Laskmanan (Author), Shaharum Shamsuddin (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Penerbit Universiti Kebangsaan Malaysia,
2021-04.
|
Online Access: | Get fulltext |
Similar Items
-
DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
by: Inés Valencia, et al.
Published: (2020-08-01) -
Potential pharmacological approach in the regulation of ACE-2 and DPP-IV in diabetic COVID-19 patient
by: Francesco Ferrara, et al.
Published: (2020-12-01) -
Global Evidence of Temperature Acclimation of COVID‐19 D614G Linage
by: Zhaonian Hao, et al.
Published: (2021-06-01) -
ACE2, Metformin, and COVID-19
by: Atul Malhotra, et al.
Published: (2020-09-01) -
Manipulation of ACE2 expression in COVID-19
by: Jagat Narula, et al.
Published: (2020-12-01)